Efficacy of a 3-day oral regimen of a quinine-quinidine-cinchonine association (Quinimax) for treatment of falciparum malaria in Madagascar.

Abstract

In the search for an effective, safe and field-adapted alternative to chloroquine for therapy of chloroquine-resistant Plasmodium falciparum infections in Africa, a 3-d oral regimen of Quinimax (an association of quinine, quinidine and cinchonine) was evaluated in 35 individuals with P. falciparum in Madagascar, an area with chloroquine resistance. 63% of the parasite strains isolated were resistant in vitro to chloroquine, and 59% of the infections were present despite previous chloroquine intake. Three daily oral doses of 10 mg/kg Quinimax for 3 d cleared parasitaemia and improved clinical status in all subjects. Mean parasite and fever clearance times were 51.7 and 37.4 h, respectively. All patients were aparasitaemic at the end of the 7-d follow-up. When formulating therapy guidelines, the 3-d Quinimax regimen should be considered as a valuable alternative to chloroquine for treating falciparum malaria in African areas with clinical resistance to chloroquine.

• Authors: P Deloron, J P Lepers, F Verdier, C Chougnet, J A Remanamirija, M D Andriamangatiana-Rason, P Coulanges, G Jaureguiberry
• Journal: Transactions of the Royal Society of Tropical Medicine and Hygiene (Trans R Soc Trop Med Hyg) 1989 Nov-Dec Vol. 83 Issue 6 Pg. 751-4 ISSN: 0035-9203 [Print] England
• PMID: 2694508 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Drug Combinations
• Chloroquine
• Quinine

Topics

• Animals
• Chloroquine (administration & dosage)
• Drug Administration Schedule
• Drug Combinations
• Female
• Humans
• Madagascar
• Malaria (drug therapy)
• Male
• Plasmodium falciparum (drug effects, isolation & purification)
• Quinine (administration & dosage, therapeutic use)